Compare Commvault Systems Inc (CVLT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Commvault Systems Inc vs TG Therapeutics Inc — how do they compare? Commvault Systems Inc trades at $156.34 (market cap $6.25B), while TG Therapeutics Inc trades at $55.11 (market cap $8.16B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and Commvault Systems Inc is more actively traded (632,727 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold Commvault Systems Inc for 17 Days and TG Therapeutics Inc for 16 Days on average.
| CVLT | TGTX | |
|---|---|---|
Market Cap | $6.25B | $8.16B |
Volume | 632,727 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $176.52 | $59.06 |
52-Week Low | $75.18 | $26.94 |
Typical Hold Time | 17 Days | 16 Days |
Enterprise Value | $6.24B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $155.16, up 3.25% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $1.42 exceeding expectations, though valuation metrics remain elevated with a P/E of 96.73. Recent positive developments include AWS Data Competency achievement and expanded FedRAMP authorization, supporting the company's AI-focused resilience platform.
CVLT presents growth potential through its AI integration and cloud partnerships, but faces risks from high valuation multiples and declining profit margins. With 54.55% analyst buy ratings and a $156.55 consensus target, the stock appears fairly valued near current levels, requiring careful monitoring of execution against growth expectations.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Commvault Systems Inc
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
